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Abstract 
The morphological variability and clinical evolution of breast cancer have prompted researchers 
to find a strategy to classify the disease and to possibly define supportive prognostic and predictive 
indicators. Recently, some studies have focused on the putative utility of miRNA as a novel class of 
cancer markers. Since potential targets of miRNAs are often provided only by bioinformatic tools there 
is a gap in this area of study. Therefore, parallel to the quantification of the expression of miR-203 and 
miR-200c in tumor tissue from patients from Central Lisbon Hospital with breast cancer, the aim of this 
dissertation was to analyze the expression of their putative targets – ATM, BMI1, SIX1 and SOX2 – by 
immunohistochemistry. 45 samples were analyzed corresponding to 43 patients whose mean age at 
diagnosis was 62 years. The most common type was invasive carcinoma NOS (71,1%) followed by 
invasive lobular carcinoma (8,9%). 86,4% of samples were ER positive, 79,1% PR positive, 13,6% 
HER2 positive and 45,5% high ki67. miR-200c was downregulated in 12,8% of the samples and 
upregulated in 23,1%. Comparatively, 20,5% of tumors presented miR-203 downregulation and 30,8% 
upregulation. Anti-ATM and anti-BMI1 antibodies didn’t perform properly thus, they were not 
assessed. Regarding to SIX1 and SOX2, only 13.3% and 8.9% of tumors were positive, respectively. 
Furthermore, a statistically significant association between the expression of both proteins and various 
clinicopathological parameters was not found, except for the number of pregnancies that seems to be 
associated with SIX1 positivity (p = 0.034). Regarding the relationship between levels of miRNAs and 
expression of their putative targets, there was no statistically association. In the future a bigger sample 
size should be used to increase the robustness of results and patient’s follow-up would allow 
evaluating the association between SIX1 and SOX2 with therapeutic outcome. 
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Resumo 
A variabilidade morfológica e clínica do cancro da mama tem levado diversos investigadores a 
procurar uma estratégia para melhor classificar a doença e, desejavelmente, definir indicadores 
prognósticos e preditivos de resposta à terapêutica. Recentemente, alguns estudos têm-se centrado 
na possível utilidade dos miRNAs como uma nova classe de marcadores de cancro. Potenciais alvos 
dos miRNAs são frequentemente identificados apenas por ferramentas bioinformáticas existindo uma 
lacuna nesta área de estudo. Por isso, paralelamente à quantificação da expressão de miR-203 e 
miR-200c no tecido tumoral de pacientes do Centro Hospitalar de Lisboa Central com cancro de 
mama, o objetivo deste trabalho foi analisar a expressão dos seus alvos putativos - ATM, BMI1, SIX1 
e SOX2 - por imunohistoquímica. 45 amostras foram analisadas, correspondendo a 43 pacientes com 
idade média, no momento do diagnóstico, de 62 anos. O tipo mais frequente foi o carcinoma invasivo 
SOE (71,1%), seguido pelo carcinoma lobular invasivo (8,9%). 86,4% das amostras eram ER 
positivas, 79,1% PR, 13,6% HER2 positivas e 45,5% com Ki67 elevado. miR-200c estava sub-
expresso em 12,8% das amostras e sobre-expresso em 23,1%. Relativamente ao miR-203 20,5% das 
amostras apresentaram sub-expressão e 30,8% sobre-expressão. Como não marcaram 
corretamente, os anticorpos anti-ATM e anti-BMI1 não foram avaliados. Relativamente ao SIX1 e 
SOX2, apenas 13,3% e 8,9% dos tumores foram positivos, respectivamente. Uma associação 
estatisticamente significativa entre a expressão de ambas as proteínas e os vários parâmetros 
clínicopatológicos também não foi encontrada, com exceção do número de gestações que parece 
estar associado com a positividade do SIX1 (p = 0,034). Quanto à relação entre os níveis de miRNAs 
e expressão dos seus potenciais alvos, não houve associação. No futuro, uma maior casuística deve 
ser usada para aumentar a robustez dos resultados e o follow-up da paciente permitiria avaliar a 
associação entre SIX1 e SOX2 e o resultado terapêutico. 
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1 Introduction 
This dissertation, titled "Immunohistochemistry detection of putative miR-200c and miR-203 Targets in 
Breast Cancer Patients", was held under the Master's Degree in Molecular Genetics and Biomedicine, 
FCT-UNL. It is inserted in a project that resulted from a partnership between the Centro de 
Investigação em Genética Molecular Humana (CIGMH), under the responsibility of professor 
Sebastião Rodrigues and Dr. Bruno Gomes, and the Surgical and Pathology Departments of the 
Breast Pathology Unit of Central Lisbon Hospital, under the responsibility of Dr.ª Paulina Lopes and 
Dr.ª Manuela Martins, respectively. The project involving the collection and analysis of human breast 
cancer samples, as well as surveys of patients, was approved by the Board of Directors of Central 
Lisbon Hospital and by the Ethics Committee thereof. 
1.1 Anatomophysiology of the Breast 
Breasts develop as downgrowths from the epidermis along the milk line which runs obliquely 
from the axilla toward the groin on each side. The nipple and its simple system of ducts are present at 
birth, but full development does not occur until puberty, and then usually only in females. Normally the 
male breast remains a rudimentary system of simple nipple ducts with a small amount of surrounding 
fibrocollagenous tissue.  Continued estrogen secretion after onset of puberty leads to progressive 
enlargement and complexity of the breast (Fig. 1.1), due initially to an increase in adipose tissue, and 
then the ductular system of the nipple becomes more complex, with branches extending into the 
adipose tissue (Stevens & Lowe, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Anatomy of the Female Breast. 
The nipple and areola are shown on the outside of the breast. The lymph nodes, lobes, 
lobules, ducts, and other parts of the inside of the breast are also shown. Source: 
https://saintfranciscare.com/saintfrancisdoctors/cancercenter/nci/CancerSummary.aspx?i
d=CDR257995.xml. 
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Inside the breasts are located the mammary glands, modified sweat glands responsible for the 
production and secretion of milk, which are composed of 12-20 distinct lobes, with its own separate 
opening at the nipple, and embedded in adipose tissue. Each lobe is a system of ever-branching ducts 
that penetrate deep into the fibroadipose tissue of the breast. The branching duct system ends in a 
cluster of blind-ending terminal ductules, each cluster and its feeding duct comprising a mammary 
lobule (Fig. 1.2). The terminal ducts and lobules are embedded in a loose fibrous support tissue, which 
is rich in capillaries and also contains a few lymphocytes, macrophages and mast cells (Seeley et al., 
2007; Stevens & Lowe, 2005). The ducts are lined by cuboidal epithelium (luminal side) with an outer 
discontinuous layer of myoepithelial cells (basal surface) (Fig. 1.3). This polarity of cellular organization 
allows transport through the mammary epithelium in a single direction: secretion into the lumen. 
Contractile myoepithelial cells have the ability to generate a flow of milk through the ducts to the nipple 
(Hinck & Näthke, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 Normal Breast histology. 
The glandular epithelium is composed of two distinct types of cells, the secretory or luminal cells 
and the myoepithelial cells. In the collecting ducts the lining cells are usually columnar whereas in 
the acini they are usually cuboidal. Adapted from 
http://www.proteinatlas.org/dictionary/normal/breast+1. 
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Breast’s full functional activity is only reached under the influence of pituitary (prolactin) and 
ovarian hormones (estrogen and progesterone), which are secreted in high concentrations during 
pregnancy and throughout breastfeeding. During the follicular phase of the menstrual cycle, cell 
proliferation is low and does not increase with the pre-ovulatory peak of estrogen. Following ovulation, 
progesterone stimulates up to three times the proliferation of the epithelial cells in the terminal 
ductules that become enlarged and begin to show evidence of early secretory activity. If fertilization 
does not occur, progesterone levels fall dramatically at the end of the menstrual cycle and the 
structure of the breast lobule reverts to normal along with some cell death. However, if fertilization 
occurs, increasing amounts of progesterone stimulate the continued proliferation and secretory activity 
in the terminal ductules of the lobule, in order to produce milk. When breastfeeding ceases, the breast 
returns to its normal state by gradual involution together with massive apoptosis leading to the loss of 
alveolar structures (Brisken, 2013; Stevens & Lowe, 2005; Vogel, 2000). Throughout a woman’s 
lifetime the breast goes through ca. 450 cycles of growth and involution in response to hormones 
produced during the menstrual cycle and pregnancy (Hinck & Näthke, 2014). As women age the 
amount of fibrocollagenous tissue in the breast increases, replacing some of the adipose tissue, and 
the mammary lobules become enclosed in dense collagen (Stevens & Lowe, 2005).  
Knowledge of normal histological appearances is essential to recognize abnormal structures, 
and to understand how the altered biochemical and physiological processes result in disease. 
 
Fig. 1.3 Schematized view of the tissue organization in breast.  
ECM: Extracellular matrix. Source: Hinck & Näthke, 2014. 
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1.2 Breast Cancer  
Because of the innumerous cycles of growth and involution in response to hormones, 
hormonal disturbances are most likely responsible for several breast pathologies, both benign and 
malignant. In most cases the development of invasive cancer appears to be preceded by carcinoma in 
situ, in which the malignant cells proliferate within the mammary ducts or lobules but do not breach the 
basement membrane. The most frequent breast invasive cancers are those that arise from the 
terminal ductolobular unit (Fig. 1.4) (Stevens et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Epidemiology  
According to GLOBOCAN 2012, breast cancer is the second most frequent cause of cancer 
death worldwide, accounting for 11.9% (1.7 million) of the total cancer cases and 6.4% (521,817) of 
the total cancer deaths worldwide in 2012. For 2014, The American Cancer Society's estimates that in 
the United States alone 232,670 new cases of invasive breast cancer will be diagnosed in women and 
40,000 women will die from breast cancer (Fig. 1.5). 
 
 
 
 
Fig. 1.4 Relationship between cellular and tissue changes in breast cancer. 
The loss of polarity is a characteristic of cancers of epithelial origin and occurs in the early stages of 
progression in the breast tissue as well as stromal remodeling due to signals from the cancer cells that 
control the activity of leukocytes, fibroblasts, endothelial and other cells, contributing to tumor 
progression, particularly for metastasis. ECM: Extracellular matrix. Source: Hinck & Näthke, 2014. 
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New Cases, Deaths 
and  
 
 
After increasing for more than 2 decades, female breast cancer incidence rates began 
decreasing in 2000. This is thought to be due to the decline in use of hormone therapy after 
menopause that occurred after the results of the Women's Health Initiative were published in 2002 that 
linked the use of hormone therapy to an increased risk of breast cancer and heart diseases. Incidence 
rates have been stable in recent years. Death rates from breast cancer have been declining since 
about 1989, with larger decreases in women younger than 50. These are believed to be the results of 
earlier detection through screening and increased awareness, as well as improved treatment 
(DeSantis et al., 2014). 
In Portugal, according to the Portuguese Cancer League (Liga Portuguesa Contra o Cancro), 
about 4,500 new cases of breast cancer are detected annually and 1,500 women die from this 
disease. 
1.2.2 Risk Factors  
Simply being a woman is the main risk factor for developing breast cancer. Men can develop 
breast cancer too, but according to the American Cancer Society this disease is about 100 times more 
common among women than men. 
Breast cancer often shows familial clustering with 5% to 10% of cases thought to be 
hereditary. Two high penetrance genes have been identified, BRCA1 and BRCA2. In families with 
BRCA1 mutations the average lifetime risk of breast cancer seems to be in the range of 55- 65%, and 
for BRCA2 mutations the risk is lower, around 45%. Low or moderate penetrance genes are also 
known and include CHEK2, PTEN, TP53, ATM, STK11/LKB1, CDH1, BRIP1 and PALB2 (Bradbury & 
Olopade, 2007; Campeau, et al.,2008; WHO, 2012). However, the etiology of breast cancer is 
multifactorial and also involves diet, reproductive factors, and related hormonal imbalances.  
Current age, age of menarche, age at first birth (or nulliparity), number of breast biopsies, 
atypical hyperplasia and number of first-degree relatives with breast cancer (ie. Mother, sisters, 
daughters) are considered risk factors in breast cancer. Compared with women who experience 
Year 1975 1980 1985 1990 1994 1998 2002 2006 
5-Year Relative Survival 75.2% 74.9% 78.4% 84.6% 86.5% 89.5% 90.3% 90.6% 
Fig. 1.5 New cases, deaths and 5-year relative survival.  
Adapted from http://seer.cancer.gov/statfacts/html/breast.html 
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menarche at age 16, girls who experience menarche two to five years earlier have a 10% to 30% 
greater risk of developing breast cancer later in life. If women who experience menopause between 
the ages of 45 and 55 years are used as referent group, women who experience menopause at age 
55 or older have a 50% higher risk of subsequently developing breast cancer. Furthermore, women 
who cease menstruating at age 45 or younger have a 30% lower risk of subsequently developing 
breast cancer (Vogel, 2000; WHO, 2012). Thus, risk increases with the number of menstrual cycles a 
woman experiences during her lifetime and hence the exposure time of the mammary epithelium to 
ovarian hormones (Brisken, 2013).  
Additionally, although current data do not support specific dietary guidelines for reducing 
breast cancer risk, the American Cancer Society still recommends that women maintain a healthy 
weight and limit intake of high-fat foods, particularly those from animal sources, as part of a healthy 
lifestyle. Obesity has been associated with an increased risk of breast cancer in post-menopausal 
women, which may occur because fat stores provide an important source of hormone substrates in 
postmenopausal women. It has not been shown clinically that reducing body weight can lower breast 
cancer risk, but this topic deserves further study. Smoking affects overall health and may increase risk 
for breast cancer, but no controlled trials have thus far established a definite link between smoking 
and breast cancer. Alcohol consumption has, however, been linked to higher serum estrogen levels; 
moderate or high amounts of alcohol consumption have been associated with increased breast cancer 
incidence. On the other hand, exercise enhances immune function, is associated with lower body fat, 
and affects hormonal levels, all of which may influence the incidence of breast cancer nevertheless, 
confounding factors make it difficult to assess this relationship, because women who exercise 
regularly are also likely to smoke less, drink less, have different menstrual and reproductive patterns, 
and consume different diets than sedentary women (Vogel, 2000; Yager & Davidson, 2006).  
Breast cancer risk is also decreased when reproductive hormone levels are altered through 
surgery.  Risks associated with the use of oral contraceptives are not well defined, though recent 
studies found that current users of oral contraceptives had a higher relative risk of breast cancer.  
Nonetheless, use of hormonal replacement therapy is associated with an increased risk of invasive 
breast cancer. Also, relatively low doses of radiation have been associated with an increased 
incidence of solid tumors such as breast cancer although very low doses of radiation associated with 
screening mammography do not increase the risk appreciably (Vogel, 2000). 
1.2.3 Diagnosis  
Most clinically significant breast disorders present as a lump and the major imperative is to 
identify those which are malignant tumors so that the patient may be treated quickly. Currently, several 
national screening programs use radiological techniques (mammography) and/or ultrasound to identify 
early suspicious breast lesions, including abnormal calcifications. A tissue diagnosis is then made by 
fine needle aspiration biopsy, core biopsy, vacuum assisted biopsy or excision biopsy before definitive 
treatment is undertaken (Stevens et al., 2002).  
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1.2.3.1 Histological classification 
Histopathologic classification is primarily based on the histological appearance of the tumor 
seen upon light microscopy of routine haematoxylin and eosin stained sections. The typing of invasive 
breast cancer and its histological variants are well established. 
Invasive carcinoma not otherwise specified (NOS) comprises the largest group of invasive 
breast cancers, comprising between 40% and 75% in published series (Fig. 1.6). It is a heterogeneous 
group of tumors that fail to exhibit sufficient characteristics to achieve classification as a specific 
histological type, such as lobular or tubular carcinoma. Invasive lobular carcinoma is the second most 
common type, representing approximately 5-15% of invasive breast cancers (Fig. 1.7). The less 
common types include mucinous, cribriform, micropapillary, papillary, tubular, medullary, metaplastic, 
and inflammatory carcinomas (Sandhu et al., 2010; WHO, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3.2 Grade 
Invasive ductal carcinomas and all other invasive tumors are routinely graded based on an 
assessment of tubule formation as an expression of glandular differentiation, nuclear pleomorphism 
and mitotic counts (total number of mitoses per 10 high power fields). A numerical scoring system of 
1-3 is used to ensure that each factor is assessed individually. The three values are added together to 
produce scores of 3 to 9, to which the grade is assigned as follows: Grade 1 - well differentiated: 3-5 
points; Grade 2 - moderately differentiated: 6-7 points; Grade 3 - poorly differentiated: 8-9 points. 
Many studies have demonstrated a significant association between histological grade and survival in 
invasive breast carcinoma. Elston and Ellis are the most recent modifications to the grading method 
used (WHO, 2012). 
 
Fig. 1.6 Invasive Carcinoma NOS. 
Invading malignant epithelial cells form small ductal structures. Adapted from 
http://www.proteinatlas.org/dictionary/cancer/breast+cancer+3 
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1.2.3.3 Stage 
The staging system currently in most widespread use is the TNM Classification. This system 
assesses cancer in 3 ways: the size and extension of the primary tumor (pT), regional lymph node 
involvement (pN), and the presence of distant metastases (pM) (Siegel et al., 2013; WHO, 2012). 
1.2.3.4 Molecular Subtypes 
Tumors show great multidimensional variation in gene expression, with many different sets of 
genes showing independent patterns of variation. These sets of genes relate to biological processes 
such as proliferation or cell signaling. Despite this variation, there are striking similarities between 
tumors, providing new opportunities for tumor classification. Using microarray technology, which 
details the expression level of thousands of genes simultaneously, several studies have shown that 
breast tumors can be grouped into at least four molecular subtypes: Luminal A, Luminal B, HER2 and 
Basal-like. Routinely, approach to defining tumors molecular subtypes is to use standard 
immunohistochemical markers, including ER (estrogen receptor), PR (progesterone receptor), HER2 
(Human epidermal growth factor receptor 2), and the proliferation marker Ki-67 (Fig. 1.8).  
Approximately 70% of invasive breast cancers are ER positive. These are collectively 
classified as luminal cancers which are subclassified into luminal A and luminal B subtypes based on 
their proliferation rate (Ki-67 expression) and HER2. The majority of ER positive tumors also express 
PR. The ER negative breast cancers are subclassified as HER2+ (~15% of all the breast cancer) and 
as triple-negative, based on the HER2 over-expression/gene amplification. Basal-like breast cancers 
(~15% of all breast carcinomas) are distinguished from other kind of triple-negative breast cancers by 
expression of CK5/6, CK14, CK17, CK34BE12 or P63. More recently, additional subtypes, such as the 
claudin-low, have been identified, while the existence of the normal like subtype is still debatable as it 
Fig. 1.7 Invasive Lobular Carcinoma. 
Malignant cells infiltrate the stroma in rows of cells which do not form ducts. Adapted from 
http://www.proteinatlas.org/dictionary/cancer/breast+cancer+4. 
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could be an artifact of gene profiling due to a disproportionally high content of normal cells. These 
breast cancer subtypes have been linked with specific molecular alterations and, equally important, 
they seem to correlate with specific incidence, baseline prognosis and response to therapy (Fumagalli 
et al., 2012; Ignatiadis & Sotiriou, 2013; Sandhu et al., 2010; Singh & Mo, 2013; Schnitt, 2010; WHO, 
2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The traditional pathological factors of lymph node status, tumor size, histological type, and 
histological grade are the most useful prognostic factors in breast cancer patients; however, they are 
now challenged by gene expression profiling. In general, the ER+ breast cancer subtypes (luminal A 
and luminal B) exhibit a good prognosis and excellent long-term survival (approximately 80%–85% 5-
year survival). The ability of patients with ER+ breast cancers to survive their disease reflects the 
availability of effective targeted therapy in the form of anti-estrogen treatment such as tamoxifen and 
aromatase inhibitors, both of which target the ER signaling. The low-grade luminal A tumors seem 
indeed indolent and may be treated only with anti-estrogens, whereas the high proliferative luminal B 
Low Ki67 
High Ki67 
Fig. 1.8 Major molecular subtypes of breast cancer determined by immunohistochemistry. 
Luminal A: ER+ and/or PR+, HER2−, and low Ki67 (<14%); Luminal B: ER+ and/or PR+ and HER2+ (luminal-HER2 group), 
or ER+ and/or PR+, HER2−, and high Ki67 (>14%); HER2: ER−, PR−, and HER2+; Basal-like: ER−, PR−, HER2−, and 
CK5/6 and/or EGFR+ (Adapted from Sandhu et al., 2010). 
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tumors often have lower expression levels of ER, lower or no PR expression, and are considered to 
have lower sensitivity to endocrine treatment and higher sensitivity to chemotherapy. In contrast, the 
ER- subtypes (HER2-positive and basal-like) are difficult to treat and are associated with poor 
prognosis (approximately 50%–60% 5-year survival). Although HER2-positive tumors have an 
aggressive progression, the survival rate has improved in the last decade due to the onset of target 
therapies using trastuzumab, an antibody against HER2, which have been shown to be effective in 
20% of patients. Basal-like tumors, despite being more aggressive than other tumor types, can be 
especially sensitive to chemotherapy but promising strategies are being developed to treat these type 
of cancer, such as poly-ADP ribose polymerase-1 inhibitors. Regarding claudin-low breast cancer, this 
subtype has a poor long-term prognosis (Ignatiadis & Sotiriou, 2013; Fumagalli et al., 2012; Sandhu et 
al., 2010; Singh & Mo, 2013; WHO, 2012). 
The purpose of breast cancer classification, subtyping and risk assessment is to, ultimately, 
select the best course of treatment for each patient. 
1.3 Novel Cancer Markers 
As previously referred, breast cancer is not a single disease; rather it represents a diverse 
spectrum of diseases including several distinct biological entities and subtypes. The complex and 
varied presentation and clinical evolution of breast cancer have long prompted professionals in the 
field to find a strategy to classify the disease and to possibly define supportive prognostic and 
predictive indicators. In a landmark report in 2000, Perou and coworkers provided a molecular 
classification of breast cancer based on gene expression profiles, which has been used as a standard 
scheme for many basic and clinical studies in the field. The molecular signatures of the five subtypes 
(luminal A, luminal B, HER2 enriched, basal-like and normal breast-like), based on differential 
immunohistochemical staining for ER, PR, HER2, and cytokeratins, among others, were shown to 
differ in terms of a number of characteristics including biology, relapse rate and response to therapy. 
The differential expression of these protein biomarkers is used as an immunohistochemical surrogate 
for gene expression analysis to determine molecular subtype (Hudson, 2013; Sandhu et al., 2010). If 
from one side it has been argued that the definition of breast cancer subtypes using 
immunohistochemistry (IHC) is not able to recapitulate the information provided by the gene 
expression intrinsic classification, from the other side it has been posited that the additional clinical 
value of the molecular classification is limited by its close correspondence to ER and HER2 status and 
proliferation markers defined by IHC (Colombo et al. 2011; Fumagalli et al., 2012).  
Nonetheless, these prognostic indicators have shown limited ability to predict individual patient 
outcomes since patients with the same clinico-pathological parameters can have largely different 
clinical courses. One plausible explanation for this phenomenon is the presence of molecular 
differences due to distinct cellular evolution in the tumor. After the initial transformation events occur, 
neoplastic cells undergo a series of changes due to the interactions between the altered cells and 
external signals. As a consequence, the incipient cancer cells arising from similar initiating events may 
diverge, resulting in neoplasms that are quite dissimilar from one another. These differences may be 
molecular (reflecting gene expression patterns), but otherwise they are not easily discernible (at the 
level of cellular morphology) and may represent the mechanisms accounting for biological subsets 
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(Fumagalli et al., 2012; Sandhu et al., 2010). Hence, further efforts should be directed at the earliest 
detection of cancer cells, which would depend on novel molecular biomarkers. 
Furthermore, the hormone receptors (ER and PR) and HER2, the only two validated predictive 
biomarkers used in the clinic, do not provide information about which chemotherapy regimen should 
be selected for adjuvant therapy (Fumagalli et al., 2012). Women receive adjuvant chemotherapy 
following the removal of detectable breast cancer tissue, to treat additional microscopic disease and 
reduce the risk of relapse and cancer-related death. Although the efficacy of this practice has been 
demonstrated, many patients currently treated with adjuvant therapy are actually overtreated. This 
underlines the importance of good prediction strategies to tailor treatment for each individual patient 
(Hudson, 2013; van der Vegt et al., 2009). It then follows that detailed molecular analysis of breast 
cancer could yield diagnostic tests that might be more accurate than existing clinical-pathological 
prediction models, or at least be complementary to them. 
Gene expression profiling is one of many new and powerful tools that have become available 
for the purpose of dissecting the biological complexity of breast cancer and improving its clinical 
course. Given that the phenotype is determined by gene expression, the clinical behavior of 
subgroups of breast cancer will be associated with specific gene expression patterns, potentially 
leading to identification of therapeutic targets or biomarkers for progression (Sandhu et al., 2010). One 
example of a microarray-based gene expression profiling currently employed in the clinical 
assessment of breast cancer is MammaPrint (Table 1.1), the 70-gene prognosis profile, which was 
approved by the Food and Drug Administration (FDA) in 2007. This test differentiates between 
patients at low risk or at high risk for metastasis on the basis of a score yielded by the assay. High-risk 
patients are recommended for more aggressive chemotherapy compared to patients with a low score. 
Another good example is the Oncotype Dx Recurrence Score, which is a 21-gene prognostic and 
predictor assay based on a continuous variable algorithm used to predict the likelihood of relapse, 
stratifying the patients that need to be aggressively treated versus those where conservative treatment 
will suffice (Colombo et al., 2011; Sandhu et al., 2010). 
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The multiplicity of tests that have been developed has created difficulties for clinicians who are 
unsure of which tests to use (Hudson, 2013). Moreover, skepticism has arisen regarding the reliability 
and the reproducibility of the microarray technology and the computational approaches used to 
develop and evaluate predictive models because different tests may contain completely different gene 
sets. Nonetheless, many genetic profiles can examine the same molecular roadmaps, given that so 
many genes are responsible for controlling the many biochemical pathways that are expressed by the 
tumor. Thus, the biological subgroups predicted by those genes are equal (Fumagalli et al., 2012; van 
der Vegt et al., 2009; De Snoo et al., 2009). The power of these signatures is their high accuracy in 
identifying low-risk patients who could be spared aggressive adjuvant chemotherapy, in contrast to 
their ability to identify high-risk patients, which could still be improved. Given these observations, it is 
justified to wonder if standard pathological biomarkers could provide similar information (Fumagalli et 
al., 2012; Rakha et al., 2008). 
Recently, some studies have focused on the putative utility of non-coding RNAs profiling, such 
as miRNA, as a novel class of cancer markers (Bartels & Tsongaliset 2009; Sandoval & Esteller, 
2012; Serpico et al., 2014). 
1.4 Biogenesis of microRNAs 
miRNAs were first discovered in 1993 when researchers found components of the genome, until 
then considered nonfunctional, with gene regulatory capacity. The lin-4 gene in C. elegans did not 
code for a protein but the coded RNA was involved in an antisense regulatory mechanism (Lee et al., 
Table 1.1 Prognostic multitude signatures in breast cancer commercially available or in commercial 
development. 
Adapted from: Colombo et al., 2011. 
real time – polymerase chain reaction 
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1993). miRNAs have since been found in plants, viruses, and more deeply branching animals (Axtell 
et al, 2011; Bartel, 2009). 
Currently, there are over 32,000 miRNA-related publications indexed in pubmed and the latest 
version of the miRBase Sequence database (mirbase.org) lists over 2,588 mature human miRNAs. 
miRNAs are now recognized as major players in almost every biological process such as cell 
proliferation, apoptosis, differentiation, and organogenesis, by regulating key processes of gene 
activation and suppression. They account for ~1% of all predicted genes in Homo sapiens and 
bioinformatics studies suggest that they control up to one third of all human genes (Tétreault & De 
Guire, 2013). Essentially, miRNAs are single-stranded RNAs, broadly conserved across species, of 
18~23 nucleotides derived from endogenous hairpin-shaped transcripts that regulate gene expression 
through a posttranscriptional mechanism (Singh & Mo, 2013).  
miRNAs (Fig. 1.9) are transcribed as long primary transcripts (up to several thousands of 
nucleotides) characterized by hairpin structures (pri-miRNAs). Approximately 50% of miRNAs have 
their own promoter and the other half can be found in intronic or exonic regions of coding or non-
coding transcription units. After transcription, pri-miRNAs are processed by RNAse III Drosha and 
DGCR8. Briefly, pri-miRNAs are cleaved into ~70 nucleotide pre-miRNAs, creating an imperfect stem 
loop structure. Then, Exportin 5, a RAN-GTP dependent nucleo/cytoplasmatic cargo transporter, 
mediates the export of the originated precursor molecules to the cytoplasm. This change in cellular 
localization allows an additional step mediated by the RNAse III Dicer which acts in complex with the 
transactivating response RNAbinding protein (TRBP) to generate a small double stranded RNA 
duplex, approximately 22 nucleotides long, that contains both the mature miRNA strand and its 
complementary strand. Dicer recognizes the double strand region of the pre-miRNA in association 
with different proteins. Completed the processing steps, TRBP then recruits Argonaute 2 (Ago2), 
which is the major component of the RISC complex (RNA Induced Silencing Complex). The role of the 
RISC complex is to select and recruit the RNA strand that has the lowest thermodynamic stability at its 
5’-end, termed the mature miRNA-3p guide strand (Iorio & Croce, 2012; Tétreault & De Guire, 2013). 
The mature single stranded miRNA product is then incorporated in the RISC complex. Guided 
by the base pairing between the noncoding RNA and the target mRNA, miRNA-RISC-mediated gene 
inhibition can be split into three processes: site-specific cleavage, enhanced mRNA degradation, and 
translational inhibition. The initial process, commonly defined as RNAi and restricted to miRNAs with a 
perfect or near-perfect match to the target RNA, is a very rare event in mammals, exclusively Ago2 
dependent. Instead, the other two processes are more commonly associated with mismatched 
miRNA/target sequences that are the most likely scenario in mammals. The combination of these two 
processes is commonly defined as a non-cleavage repression (Bartels & Tsongaliset 2009; Iorio & 
Croce, 2012). 
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Most of the time, miRNAs mainly bind their targets via a sequence between their 2nd and 8th 
nucleotides of their 5’ extremity: the seed sequence. Although interaction between the miRNA 
sequence of the 9th to 20th nucleotide of small RNAs is required, a perfect complementary between a 
miRNA and the 3’-untranslated regions (UTRs) sequence of their target mRNAs is not necessary. The 
limited complementary was first considered as a weak-point; however, this property holds intrinsic 
advantages for the regulation of gene expression by miRNAs. Moderate affinity of one miRNA for a 
given target allows a single miRNA to inhibit simultaneously the expression of hundreds of different 
mRNAs. Since many of these miRNA targets are involved in various signaling pathways, their impact 
on gene expression can be significantly amplified. Moreover, bioinformatics analysis predicts that 3’-
UTRs of single genes are often targeted by several different miRNAs. Although less frequently, 
miRNA can also bind to the 5’-UTR or the ORF and, even more surprisingly, they can upregulate 
translation upon growth arrest conditions (Iorio & Croce, 2012; Singh & Mo, 2013; Tétreault & De 
Guire, 2013). 
Apart from the cells in which they are produced, miRNAs can be found in blood, urine, saliva 
and many other biological fluids. Not only detectable in blood cells, an important fraction of blood 
circulating miRNAs is found in a free state that may include transportation in exosomes and 
lipoproteins, as well as bound to proteins. For that reason, some consider miRNAs as hormones 
because, when secreted into circulation by a mother cell, miRNAs can regulate gene expression of a 
distant cell following endocytosis (De Guire et al., 2013; Tétreault & De Guire, 2013). 
Fig. 1.9 The mechanism of microRNA biogenesis and regulation of gene expression. 
Source: Li & Yang, 2013. 
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1.5 miRNA and Cancer 
Cancer has traditionally been viewed as a set of diseases that are driven by the accumulation of 
genetic mutations that have been considered the major causes of neoplasia. However, this paradigm 
has now been expanded, since tumorigenesis is a multistep process, including initiation, promotion 
and progression, and a multifactorial pathology characterized by the accumulation of a multitude of 
alterations including genetic, cytogenetic, and epigenetic changes. The epigenetic pathway to cancer 
is not simple and is determined by chromatin structure remodeling including DNA methylation, histone 
variants modifications, nucleosome remodeling as well as small non-coding regulatory RNAs. 
Importantly, alterations in epigenetic mechanisms can lead to genetic mutations, and genetic 
mutations in epigenetics regulators lead to an altered epigenome (You & Jones, 2012; Sandoval & 
Esteller, 2012). 
The link between miRNA dysregulation and human disease has been reported in almost all 
medical fields (Tétreault & De Guire, 2013). To date, according to the Human MicroRNA Disease 
Database (HMDD), research has demonstrated that miRNAs are associated to 378 human diseases 
(Li et al., 2013a). The first link of the involvement of miRNA in human cancer derived from studies on 
chronic lymphocytic leukemia by Dr. Croce’s group who showed the first evidence that miRNAs could 
be involved in the pathogenesis of human cancer as the chromosome deletion caused the loss of miR-
15a and miR-16-1 (Calin et al., 2008). 
The widespread differential expression of miRNA genes between malignant and normal cells is 
a complex phenomenon and can be exerted through several mechanisms, all acting in concert for 
abnormal expression levels of miRNAs: chromosomal abnormalities, mutations, polymorphisms, 
defects in miRNA biogenesis machinery, epigenetic changes, or transcription activity dysregulation of 
a transcription factor at the promoter (Iorio & Croce, 2012; Nicoloso et al., 2009; Serpico et al., 2014). 
It is now well characterized that the genomic sequences of 50% of miRNAs are located at cancer-
associated genomic regions which are fragile sites that are either deleted or amplified in cancer 
(Croce, 2009; De Guire et al., 2013; Nicoloso et al., 2009). Indeed, chromosomal regions 
encompassing miRNAs involved in the negative regulation of a transcript encoding a known tumor 
suppressor gene can be amplified in cancer development. This amplification would result in the 
increased expression of the miRNA and consequent silencing of the tumor suppressor gene, being, 
therefore, designated as oncogenic miRNAs (oncomiRs). Conversely, tumor suppressor miRNAs 
(tsmiRs) repress oncogenes and are often located in fragile loci, where deletions or mutations can 
occur and result in reduced microRNA levels and overexpression of the target oncogene (Fig. 1.10). It 
is important to note that miRNAs may act in a tissue-specific way such that a single miRNA type can 
be either an oncomiR or a tsmiR in different types of tumors (Iorio & Croce, 2012; Li & Yang, 2013; 
Serpico et al., 2014). Either as tsmiRs or oncomiRs, there are essential features of cancer progression 
in which miRNAs may act: self-sufficiency in growth signals, insensitivity to anti-growth signals, 
apoptosis evasion, limitless replicative potential, sustained angiogenesis, tissue invasion and 
metastasis (Iorio & Croce, 2012). 
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Since microRNAs have multiple targets, their function in tumorigenesis could be due to their 
regulation of very few specific targets, possibly even one, or many targets. A future challenge will be to 
identify all the targets of the microRNAs involved in cancer and establish their contribution to 
malignant transformation in vivo. An additional challenge will be the identification of all the microRNAs 
that are dysregulated by pathways that are consistently dysregulated in various types of human 
cancers. This point is of particular potential importance, since instead of focusing on the specific 
alterations in protein coding oncogenes or tumor suppressor genes that are components of the 
pathways dysregulated in cancer, that may be difficult to be addressed therapeutically, we may focus 
on their downstream microRNA targets (Croce, 2009). 
Of considerable interest, a unique miRNA expression pattern can be associated with certain 
breast cancer subtypes (Table 1.2). For example, miR-21, miR-210 and miR-221 are significantly 
overexpressed in triple-negative breast cancer, whereas miR-10b, miR-145, miR-205 and miR-122a 
are significantly underexpressed in these cancer types. Furthermore, miR-21, miR-210 and miR-221 
correlate with worse patient disease-free and overall survival, and hence they play a significant role in 
triple-negative primary breast cancers (Singh & Mo, 2013). 
 
 
Fig. 1.10 The role of microRNA in cancer. 
Source: Li &Yang, 2013. 
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In addition, miRNAs can specifically classify estrogen receptor (ER), progesterone receptor 
(PR) and HER2 receptor status (Iorio & Croce, 2012). ER, which serves as the target of endocrine 
therapeutic agents such as tamoxifen and raloxifen, is regulated by let-7, miR-206, and miR-221 in 
breast cancer. Interestingly, miR-206 and miR-221 are believed to be responsible for tamoxifen 
insensitivity, while induction of tamoxifen sensitivity by let-7 could be due to a different binding region 
(Li & Yang, 2013). On the other hand, miR-21 upregulation has been associated to Trastuzumab 
resistance in HER2-positive breast cancers (Serpico et al., 2014). Besides hormonal therapy, miRNAs 
are closely related to chemoresistance (Table 1.3). For instances, the ABC transporter MDR1 gene has 
been shown to be directly regulated by miR-200c that induces chemosensitivity to doxorubicin. 
Alternatively, SOCS3 has been shown to be regulated by miR-203, inducing chemoresistance to 
Cisplatin (Singh & Mo, 2013). These resistance/sensitivity can be mediated by miRNAs through 
regulating drug resistance-related proteins, altering drug targets, changing drug concentration, 
influencing therapeutic induced cell death, promoting angiogenesis, influencing tumor stem cell, and 
promoting epithelial-mesenchymal transition (EMT) (Li & Yang, 2013; Zhou, 2013a). 
 
Table 1.2 miRNAs and breast cancer subtypes. 
Source: Serpico et al,, 2014. 
Table 1.3 miRNAs and multigdrug resistance. 
Source: Tian et al., 2013. 
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While numerous miRNAs have been shown to control EMT during breast tumor progression, 
recently miRNAs have been identified that govern multiple aspects of metastasis, including 
microenvironmental remodeling, in addition to epithelial plasticity (Fig. 1.11) (Hinck & Näthke, 2014; 
Nicoloso et al., 2009; Wang & Wang, 2012). miR-148b, for instance, is downregulated in aggressive 
breast tumors and has been found to be a major coordinator of malignancy by regulating over 130 
genes involved in epithelial cell motility and stromal cell proliferation (Hinck & Näthke, 2014). The well-
characterized miR-200 family and let-7 family, beyond the regulatory role in normal development and 
tumorigenesis, also inhibit invasion, metastasis, and EMT of breast cancer (Liu, 2012). In addition, it 
was recently showed that cancer cell-derived miRNAs could bind to Toll like receptor of immune cells 
and act as agonist to induce a pro-metastatic inflammatory response (De Guire et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.11 Summary of miRNA regulators and biomarkers in the development of the normal mammary 
gland, breast cancer initiation, metastasis, and therapy resistance. 
MaSC: mammary stem cells; Br Ca: breast cancer; ER: Estrogen receptor; PR; Progesterone Receptor; DRFS: 
Distant relapse-free survival. Source: Liu, 2012. 
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Besides the use as predictive biomarkers, the correlation between microRNA expression and 
response to specific therapies has also suggested their promising potential as therapeutic adjuvant 
(Iorio & Croce, 2012; Liu, 2012). However, because miRNAs target a broad range of target genes in a 
context-dependent manner, they may also elicit unexpected effects in certain cells or tissues (Liu, 
2012). For that reason, the miRNAs and antagomiRs agents are still in preclinical studies and in vitro 
toxicity studies are underway (Nicoloso et al., 2009). To date, 17 trials are found in ClinicalTrials.gov 
for the keywords “miRNA” + “breast cancer” and they all refer to miRNA profiling. 
Overall, there is still a long way to go before miRNA-targeted therapies as effective approaches 
for the sequence-specific inhibition of miRNAs in breast and other tumors become a reality, and using 
miRNAs as diagnostic and prognostic markers remains a scientific and clinical challenge (Wang & 
Wang, 2012). 
1.6 miRNA as a cancer marker 
The use of genome-wide approaches has enabled the production of miRNAs fingerprints in a 
range of tumors and its normal counterpart (Bartels & Tsongaliset 2009; Sandoval & Esteller, 2012; 
Serpico et al., 2014). As a result, miRNA expression signatures (miRNome) allowed different types of 
cancer to be discriminated with high accuracy and the tissue of origin of poorly differentiated tumors to 
be identified. For example, Rosetta Genomics® developed an algorithm based on 48 miRNAs that 
identified the origin of cancers of unknown primary with an accuracy of 90%. By contrast, mRNA 
profiles are highly inaccurate indicators of tissue or cancer type. Given that cancers of undefined origin 
account for approximately 4% of all malignancies and are associated with poor prognosis, the 
continued development of miRNA classifiers has foreseeable benefits in aiding clinical diagnosis and 
subsequent treatment (De Guire et al., 2013; Iorio & Croce, 2012). 
In addition, information contained in the RNA of the tumor cells is degraded when the tissue is 
processed and embedded in paraffin, the most common procedure for tumor storage (De Snoo et al., 
2009; van der Vegt et al., 2009). miRNAs are certainly more stable due to their small size as 
compared to long mRNAs, allowing expression profiling from fixed tissues or other biological material, 
and thus supporting their possible use as novel, minimally invasive and robust biomarkers (Iorio & 
Croce, 2012; Liu, 2012). 
Moreover, there’s a specific signature of miRNAs for a wide range of disease in blood, urine, 
saliva and many other biological fluids and the profile of circulating miRNAs has been shown to reflect 
the pattern observed in the tumor tissues. For instances,  Henegan et al. identified breast cancer 
patients with a sensitivity and specificity of 87.7% and 91% by measuring the circulating levels of miR-
195. Even more impressively, overexpression of miR-205 and miR-21 in ductal adenocarcinoma has 
been reported to precede phenotypic changes in the ducts. This suggests the attractive possibility of 
using circulating miRNAs as easily detectable tumor biomarkers, especially for early diagnosis (De 
Guire et al, 2013; Iorio & Croce, 2012; Tétreault & De Guire, 2013). 
In a preliminary study in our lab, an expression plate for 95 miRNAs (QuantiMir™ Cancer 
MicroRNA qPCR Array) was performed on the breast cell lines MCF-10A (non tumoral line), MCF-7 
(tumor line) and MDA-MB-231 (metastatic tumor line).  Some miRNAs with dysregulated expression 
were identified, including miR-203a and miR-200c. The dysregulated expression was confirmed with 
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miRCURY LNA™, a miRNA-specific, LNA™-based system designed for sensitive and accurate 
detection of microRNA by quantitative real-time PCR using SYBR® Green. Briefly, our data indicate 
that miR-203a was overexpressed on MCF-7, when compared to all other breast cell lines, and miR-
200c was underexpressed in tumor cell lines when compared to the non tumoral line (data not 
published). Hence, miR-203a may be associated with tumorigenesis and possibly ER status, since of 
these three cell lines MCF7 is the only to express ERα, and miR-200c could be associated with a 
better prognosis, given that its expression decreases with the tumor aggression.  
1.7 miRNAs Targets 
Regarding the identification of miRNA targets, some computational tools are available that can 
take advantage of algorithms developed for miRNA target prediction such as “Targetscan”, “EMBL”, 
“PicTar”, “EIMMo”, “Miranda”, “miRBase Targets”, “PITA”, “mirWIP”, “RNA22”, “Tarbase”, “microRNA”, 
“Diana-microT”, “miRecords” and “Starbase”. TargetScan is the one with the most robust 
discrimination rankings (Bartel, 2009; Iorio & Croce, 2012). 
This identification has been difficult because most of the times only the seed sequence (about 
6–8 bases) of the approximately 22 nucleotides aligns perfectly with the target mRNA’s 3’-UTR. 
Therefore, bioinformatics approaches can only identify putative targets for particular miRNAs through 
analysis of the miRNA seed sequences. As a result, these miRNAs need to be assayed in vitro or in 
vivo to determine if they truly affect the proposed mRNA because in many cases the predicted targets 
are not real targets. However, since the number of predicted targets is large, this approach is rather 
laborious (Bartels & Tsongaliset 2009; Croce, 2009). 
The vast number of predicted targets, often with quite disparate functions, presents 
researchers with the challenge of choosing which is worthy of experimental follow-up. In some cases, 
known properties of a predicted target will suggest that the biological process of interest might be 
particularly sensitive to changes in its expression, making it especially promising for follow-up. Another 
way to choose targets to investigate is to assume that those messages with multiple conserved sites 
and particularly favorable sites might be among the most responsive to the miRNA (Bartel, 2009). 
Therefore, in order to select targets that could be of interest in the context of breast cancer, 
according to some publications and to their function at the cellular level, we used TargetScan to find 
transcripts with conserved sites for miR-203 and miR-200c, the miRNAs that we previously indentify in 
breast cancer cell lines. As targets we selected ATM (target of miR-203), BMI1 (target of miR-203 and 
miR-200c), SIX1 (target of miR-200c), and SOX2 (target of miR-200c). 
1.7.1 ATM 
Cellular sensitivity to DNA damaging agents such as radiotherapy and radiomimetic drugs are 
regulated by a cascade of DNA damage response proteins. Among them is ATM (ataxia-telangiectasia 
mutated). ATM gene is mutated in the autosomal recessive disorder Ataxia-Telangiectasia, manifested 
by progressive neuronal degeneration, cancer predisposition, immunodeficiency and hypersensitivity 
to radiotherapy (Guo et al., 2013; Hesse et al., 2013). This gene encodes a serine/threonine kinase, 
member of the phosphoinositide 3-kinase (PI3-kinase)-like family (PIKK). ATM is a nuclear 
phosphoprotein activated in response to double strand DNA breaks damage, with a more general role 
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in signal transduction and in maintaining the stability of the genome by phosphorylation and activation 
of a series of downstream targets, such as CHK1, CHK2, BRCA1, 53BP1, and MDC1 which signal to 
DNA repair coordinators such as BRCA2, PALB2 and to cell cycle checkpoints and the apoptotic 
machinery. There is significant cross-talk between the various pathways of damage response 
depending on the nature and severity of the DNA damage (Caldo, 2014; Cuatrecasas et al., 2006; 
Guo et al., 2013). 
ATM mRNA is downregulated in breast cancers when compared with normal tissue by 
competitive RT-PCR. Low ATM expression might thus have effects on crucial cell cycle checkpoints, 
allowing cells that harbor DNA damage to divide and acquire genetic alterations leading to increased 
tumor grade (Cuatrecasas et al., 2006). 
Additionally, about half of unselected breast cancer patients have been reported to be 
heterozygotes for ATM mutations in some series. While heterozygous carriers do not suffer from 
ataxia telangiectasia syndrome, they have an increased risk of developing heart disease, diabetes, 
and cancers, specifically breast cancer, compared to individuals with normal ATM expression levels. 
Hence, ATM has been proposed as a candidate tumor suppressor with a potential pathogenic function 
in breast carcinomas (Cuatrecasas et al., 2006; Hesse et al., 2013). Nonetheless, ATM 
hyperactivation has been observed in many stages of tumor tissues. In the early stage of 
tumorigenesis is oncogene driven and represents the antitumor function of the kinase. However, in 
late stages contributes to breast cancer metastasis. Moreover, since radiation induces ATM 
autophosphorylation increasing its protein kinase activity, the use of specific ATM inhibitors might 
achieve more clinical benefits as this might specifically increase tumor sensitivities to many of the 
chemotherapeutic drugs as well as radiotherapy (Guo et al., 2013). 
ERα downregulates transcription of ATM via the activation of miR-18a and miR-106a, which 
interferes with the induction of cell cycle checkpoints so that cells continue to progress through the cell 
cycle after DNA damage, and DNA repair is delayed or not engaged. This could explain why ATM 
levels are higher in ER negative breast cancers and its high expression correlated with recurrence in 
breast cancer (Caldo, 2014; Guo et al., 2013). Moreover, ATM can also be regulated by directly 
binding of miR-203 to the ATM 3’-UTR site, as demonstrated in colorectal cancer (Zhou et al., 2013b).  
1.7.2 BMI1 
BMI1 (BMI1 polycomb ring finger oncogene) which encodes a polycomb ring finger protein, 
was identified as a proto-oncogene cooperating with c-Myc during the initiation of lymphomas. It has 
subsequently been identified as a transcriptional repressor belonging to the polycomb group (PcG) 
proteins, and is also a key factor in the polycomb repressor complex 1 (PRC1), which serves as an 
important epigenetic regulatory complex for modulation of chromatin remodeling. To date, many PRC1 
target genes have been identified including homeobox (HOX) genes and p16INK4a, whose promoters 
contain interactive elements which bind directly to BMI1 (Wang et al., 2014; Yin et al., 2013).  
A striking finding in recent studies is that the activity of BMI1 is indispensable for cell survival 
and self-renewal of stem cells or cancer stem cells. Over-expression of BMI1 has been found in a 
large number of human cancers, including breast cancer, which indicates that BMI1 might play 
important roles in cancer initiation and progression. Some molecular mechanisms underlying the role 
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of BMI1 in cancer have been proposed, such as inhibition of the tumor suppressors p16INK4a and 
p14ARF, and PTEN to promote EMT and malignancy. In addition, investigation has shown that BMI1 
expression is positively correlated with ER status in breast cancer, since it is induced mainly by ERα. 
However if there is no expression of ERα, BMI1 may be induced by other factors such as E2F1 and 
MYC, both of which are usually expressed in cancers (Parvathi et al.,2013; Wang et al., 2014; Yin et 
al., 2013). 
BMI1 might be used as a diagnostic and prognostic marker of human cancer. In particular, in 
patients suspected of having breast cancer, BMI1 mRNA can be detected with highly sensitive RT-
PCR and may be a good marker to support diagnosis even when very few cells are obtained (Parvathi 
et al., 2013). 
Furthermore, functional studies support a pivotal role of miR-200c and miR-203 in regulating 
self-renewal of mammary stem cells through a direct targeting of BMI1 3’-UTR. On the contrary, BMI1 
can also inhibited miR-200c expression, but not miR-203 (Liu, 2012; Yin et al., 2013). 
1.7.3 SIX1 
In vertebrates, the Six family is classified into three subgroups, SIX1/SIX2 (So), SIX3/SIX6 
(Optix), and SIX4/SIX5 (Dsix4), which are characterized by a Six-type homeodomain and Six-domain. 
The SIX family members are known to play an important role in the expansion of precursor 
populations prior to differentiation. SIX homeobox 1 (SIX1), the most extensively investigated, is 
involved in the development of many tissues and organs, such as muscle, kidney, auditory system, 
sensory organs and craniofacial structures. SIX1 is broadly expressed in various tissues and organs, 
although levels vary, and throughout developmental from embryo to adulthood, suggesting that there 
may be a basic promoter sequence to maintain its basic expression in these various contexts. In 
addition, much attention has been paid to the role of SIX1 in tumorigenesis, including breast cancer 
(Jin et al., 2014; Wu et al., 2014). SIX1 mRNA is overexpressed in 50% of primary breast cancers, 
and in a much larger 90% percent of metastatic lesions, suggesting that it may be involved in more 
than just tumor initiation (Iwanaga et al., 2012). 
SIX1 overexpression can activate breast cancer cell proliferation and stimulate tumorigenesis 
by directly activating cyclin A1 transcription, a critical factor in cell proliferation, survival, DNA repair 
and angiogenesis. Other pro-tumorigenesis genes are also regulated by SIX1 (e.g., cyclin D1, c-Myc, 
and Ezrin). In addition to the role that SIX1 plays in proliferation and survival, its overexpression also 
leads to the induction of an epithelial to EMT via upregulation of TGF-b signaling and may also 
increase the cancer stem cell or tumor initiating cell population via its ability to activate both the TGF-b 
signaling and MEK/ERK signaling pathways. SIX1 can induce as well lymphangiogenesis and distant 
metastasis by up-regulating VEGF-C in breast cancer (Iwanaga et al., 2012; Li et al., 2013b; Wu et al., 
2014). 
Moreover, elevated expression of SIX1 is associated with relapse of breast cancer treated with 
paclitaxel-containing chemotherapy. Hence, overexpression of SIX1 correlates significantly with worse 
survival (Iwanaga et al., 2012; Li et al., 2013b). 
Surprisingly, a recent study found that microRNA-185 can inhibit SIX1 expression, resulting in 
the suppression of tumor growth. Because a single gene may be targeted by one or multiple miRNAs 
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SIX1 is likely to be regulated by other miRNAs (Wu et al., 2014). In fact, according to TargetScan, 
SIX1 mRNA is targeted by several miRNAs including miR-200c. 
1.7.4 SOX2 
The recent interest in stem cell research and its clinical implications have brought into focus 
transcription factors of the sex-determining region (SRY)-related high mobility group (HMG)-box family 
(SOX family). SOX2 is widely regarded as a key founding member of the cohort of core transcription 
regulators that controls pluripotency and self-renewal in embryonic stem cells by physically interacts 
with OCT4 and NANOG forming a protein complex that binds the promoters of numerous stem cell 
differentiation factors, suppressing their expression. Thus, SOX2 plays critical roles in the embryonic 
development of several tissues and in organogenesis. It is expressed in stem cells and precursor cells 
during development, displaying a restricted spatial-temporal pattern, and therefore it is likely to be 
involved in self-renewal and precursor differentiation. Due to its role in maintenance of embryonic 
stem cells and tumorigenesis, SOX2 has been implicated as a marker for cancer stem cells (Huang et 
al., 2014; Lengerke et al., 2001; Tam & Ng, 2014; Zhang et al., 2012). 
Consistent with their role in sustaining stemness of embryonic stem cells, pluripotency-related 
factors have been suggested to be expressed with higher frequency in tumors displaying lower 
degrees of differentiation (Lengerke et al., 2001). However, to date, little is known about the role of 
SOX2 during breast tissue development, and no significant SOX2 expression has been detected in 
healthy human breast tissue. There is, however, increasing evidence showing that SOX2 is expressed 
in human breast cancers. These suggest that SOX2 plays a role in breast cancer tumorigenesis 
(Huang et al., 2014; Zhang et al., 2012). 
SOX2 appears to be preferably expressed in basal-like breast carcers. This observation 
indicated that SOX2 expression decreases upon tumor cell differentiation, raising the possibility that 
SOX2 may be important in maintaining the ‘low differentiation’ status, tumor progression and lymph 
node metastasis of breast cancer (Huang et al., 2014; Lengerke et al., 2001). 
Interestingly, it was found that miR-200c regulates SOX2 expression through a feedback loop 
and is associated with colorectal carcinoma stemness, growth, and metastasis (Lu et al. 2014). 
1.8 Goals 
Since potential targets of miRNAs are often provided only by bioinformatic tools there is a gap in 
this area of study, which leads to the topic of this dissertation. Therefore, parallel to the quantification 
of the expression of these miRNAs in tumor tissue from patients with breast cancer, it is necessary to 
observe the expression of these miRNAs targets described bioinformatically, in order to infer if in vivo 
when a miRNA is overexpressed its targets are downregulated and subsequently the respective 
protein is underexpressed, and vice-versa. 
Hence, the aim of this dissertation is to analyze the expression of miR-203 and miR-200c putative 
targets – ATM, BMI1, SIX1 and SOX2 – in breast cancer samples by immunohistochemistry. 
As specific objectives we delineated the following: 
• To determine the expression of ATM, BMI1, SIX1 and SOX2 in breast cancer samples by 
immunohistochemistry; 
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• To compare immunohistochemistry profile of ATM, BMI1, SIX1 and SOX2 with histologic 
characteristics of breast cancer samples and; 
• To compare immunohistochemistry profile of ATM, BMI1, SIX1 and SOX2 with miR-203 
and miR-200c expression of breast cancer samples 
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2 Materials and Methods 
2.1 Breast Cancer Samples 
Blood samples, fresh tumor samples preserved in RNALater and formalin fixed and paraffin 
embedded (FFPE) tumor and normal counterpart tissue were collected from patients diagnosed and 
subject to lumpectomies between 2013 and 2014. Collection of biological samples and clinical / 
personal information was carried out by the Surgical and Pathology Departments of the Breast 
Pathology Unit of Central Lisbon Hospital, in accordance with the Declaration of Helsinki; the 
confidentiality of patients was fully safeguarded. To date, the biobank is composed of 121 diagnosed 
and characterized samples from a total of 115 patients. Samples were diagnosed, graded according to 
Elston-Ellis, and staged under the competence of pathologist Dr.ª Manuela Martins, and were further 
characterized for ER, PR, HER2 and Ki67 expression by immunohistochemistry. The majority of 
tumors were invasive carcinomas NOS, accounting for 66.4% of all tumors collected. The remaining 
were invasive lobular carcinomas (12.6%), carcinomas in situ (6.7%), mucinous carcinoma (3.4%), 
invasive papillary carcinoma (2.5%), invasive micropapillary carcinoma (2.5%), invasive cribriform 
carcinoma (0.8%), medullary carcinoma (0.8%), neuroendocrine tumor (0.8%), intraductal carcinoma 
(0.8%), sebaceous carcinoma (0.8%), mixed type carcinoma (0.8%), or glycogen-rich clear cell 
carcinoma (0.8%). 88.8% of the samples were estrogen positive (>1% stained cells), 82.3% 
progesterone positive (>1% stained cells), 12.3% HER2 positive (3+ by immunohistochemistry or gene 
amplification by FISH)  and 46.5% high ki67 (>14% stained cells). Women’s mean age at diagnosis 
was 63 years (range 35-86). 91 of these women were postmenopausal and 1 was perimenopausal. 
35.7% were classified as lymph node positive. 
2.2 miRNA Quantification 
miRNAs quantification was performed at CIGMH by Dr. Bruno Gomes. Total RNA was extracted 
from the same FFPE tissue samples of breast cancer used for diagnosis, and normal counterpart. 
From tumor specimens ten sections of 10 µm were collected whereas from normal counterpart a 
punch was made in the sample to guarantee that only nontumoral tissue was collected. RNA was 
isolated following the manufacturer’s protocol (RecoverAll™ Total Nucleic Acid Isolation Kit - 
ambion™ Total Nucleic Acid Isolation Kit – ambion® by life technologies™). Briefly, samples were 
deparaffinized with xylene at 50ºC, washed with ethanol and then air dried. Next, protein digestion was 
achieve with a protease incubation for 15 min at 50ºC followed by 15 min at 80ºC. After dilution in an 
isolation additive/ethanol mixture the samples were filtered for nucleic acid isolation. For purification, 
the samples were treated with a DNase for 30 min at room temperature and then filtered again. Elution 
was made with RNase-free water and the total RNA concentration measured using NanoDrop 1000 
(Thermo Scientific). Samples were stored at -80°C.Template RNA was then adjusted to 5ng/µL and, 
using miRCURY LNA™ Universal RT microRNA PCR (Exiqon), incubated with enzyme mix for 60 min 
at 42ºC followed by heat-inactivation of the reverse transcriptase for 5 min at 95ºC. Samples were 
immediately cool to 4ºC. No reverse transcription enzyme and no sample negative controls were 
included. For real-time PCR amplification the cDNA was diluted 80x, merged with PCR Master mix 
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and PCR primer mix for miR-203 or miR-200c and inserted in the cycler for a 40 amplification cycles 
run (10sec at 95ºC and 1 min at 60º). Threshold cycles were defined manually for the first cases and 
used for the remaining samples. 
A fold-change expression was calculated to the tumor samples relatively to the normal counterpart 
and a cut-off established as follows: 
• If fold-change ≤ -2.5, the miRNA was considered underexpressed in the tumor relatively to 
the normal counterpart; 
• If fold-change ≥ 2.5, the miRNA was considered overexpressed in the tumor relatively to 
the normal counterpart; 
• If fold-change > -2.5 and < 2.5, it was considered that the miRNA levels do not vary 
between tumor and normal tissue. 
2.3 Immunohistochemistry 
2.3.1 Optimization 
Immunohistochemistry (IHC) technique was implemented from scratch. Moreover, as the work 
conditions of the primary antibodies may not correspond to the ones recommended by the 
manufacturer there was also the need to previously identify, for each primary antibody, the optimal 
dilution that satisfied the requirements of this study. For each target, we purchased 2 antibodies that 
were subject to optimization prior to application in the patients’ samples: 
• Anti-ATM, rabbit, monoclonal, clone Y170, Millipore, lot 2445819, ref. 04-200; 
• Anti-ATM, rabbit, monoclonal, clone Y170, Millipore, lot 2472976, ref. 04-200; 
• Anti-BMI1, mouse, monoclonal, clone 229F6, Nordic-MUbio, lot 1362, ref. MUB2004S; 
• Anti-BMI1, mouse, monoclonal, clone 10H8, Cell Applications, lot 101, ref. CB16351; 
• Anti-SIX1, rabbit, polyclonal, Sigma-Aldrich, lot B40182, ref. HPA001893; 
• Anti-SIX1, mouse, monoclonal, clone CL0185, Sigma-Aldrich, lote 02582, ref. 
AMAb90544; 
• Anti-SOX2, rabbit, polyclonal, Sigma-Aldrich, lote S9072, ref. S9072; 
• Anti-SOX2, mouse, monoclonal, clone 10F10, Sigma-Aldrich, lot PM12110682, ref. 
SAB5300177. 
The tissue sections used as positive controls – normal breast tissue for ATM and BMI1, normal 
cervix for SIX1, and normal tonsil for SOX2 – were cut at the Pathology Department of Central Lisbon 
Hospital. Immunohistochemistry to assess the optimal conditions was performed manually at CIGMH 
and the main steps that were adjusted were: 
• Antigen retrieval – duration (10min-20min), microwave potency (50-100%) and buffer (tris-
EDTA pH9 or citrate pH6), and; 
• Primary antibody incubation – duration (30min-60min), and dilution (1/50-1/2000).  
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Optimal dilution was considered the one which allowed more specific staining intensity in all 
expected structures of the positive control sample with no background or nonspecific staining. 
Although all antibodies have been tested , only two were optimized. 
2.3.2 Technique 
IHC technique (Table 2.1) was performed manually (Fig. 2.1) on the same FFPE breast cancer 
samples from which total RNA was extracted for miRNA quantification. So far, 45 samples of the 
biobank were analyzed, corresponding to 43 patients. Merely tumor samples were used since normal 
mammary gland was also present in all of them, avoiding the need to use another sample only to 
observe the protein expression in the normal counterpart.  
 
Serial 2-3µm paraffin sections were cut onto Superfrost® Plus slides (Thermo Scientific, ref. 
J1800AMNZ) at the Pathology Department of Egas Moniz Hospital (Fig. 2.2). The subsequent steps 
were performed at CIGMH. For proper adhesion, sections were left overnight at 37ºC and then put in 
microwave for 2 minutes at full potency. Then, they were deparaffinized in Xylene, and rehydrated. 
Antigen retrieval was achieved in MW with Tris-EDTA Buffer (10mM Tris Base, 1mM EDTA Solution 
with 0.05% Tween 20, pH 9.0), and endogenous peroxidase activity blocked with 3% Hydrogen 
Peroxide. Protein block was performed with ready-to-use (2.5%) normal horse blocking solution 
(Vector Laboratories, ref. MP-7402), and then sections were incubated (Fig. 2.3 - A) at room 
temperature with: 
• Anti-SIX1 antibody (mouse, clone CL0185, Sigma-Aldrich), dilution 1:100, for 1 hour 
or; 
• Anti-SOX2 antibody (mouse, clone 10F10, Sigma-Aldrich), dilution 1:500, for 30 
minutes. 
Antibodies were diluted in Phosphate buffer saline (PBS) (137mM NaCl, 2,7mM KCl, 10mM 
Na2HPO4, 1,8mM KH2PO4, with 0.05% Tween 20, pH 7.4). Bound antibody was visualized using 
ready-to-use ImmPRESS™ anti-mouse Ig detection kit (Vector Laboratories, ref. MP-7402) (Fig. 2.3 - 
Fig. 2.1 Immunohistochemistry technique being performed 
manually. 
Fig. 2.2 Tumor section of ~2 µm after being 
cut on a micrtotome. 
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B) based on horseradish peroxidase (HRP) and 3,3’-diaminobenzidine (DAB) (Invitrogen, ref. 88-2014) 
(Fig. 2.3 - C). Slides were counterstained with Mayer’s Hematoxylin (Sigma-Aldrich, ref. MHS80) (Fig. 
2.3 - D). Subsequently, sections were washed, dehydrated in a graded alcohol series, clarified in 
Xylene and mounted with Entellan® (Merck, ref. 1.07961.0500). 
In order to validate the results of samples that eventually did not express the studied protein, we 
included, per run, a slide containing a section of a tissue with known expression that served as control, 
the same kind that was used during optimization step. That way we could guarantee that the 
technique performed appropriately.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Fig. 2.3 Schematic representation of what happens during immunohistochemistry of the tumor section, macroscopically 
and at molecular level. 
A) Mouse primary antibody (red) specifically recognize its epitope; B) ImmPRESS™ anti-mouse Ig (blue) recognizes the primary 
antibody FC region; C) DAB (purple) is converted by HRP enzymes (orange) of the detection system in a insoluble precipitate 
(brown). D) Hematoxylin stains de nuclei giving contrast to a tissue previously translucent. 
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Table 2.1 Immunohistochemistry Protocol.  
All the steps were performed at room temperature except for antigen retrieval (step 4). In this step, the buffer, in 
which the slides are dipped, was boiled in a microwave. Same amount of slides were always used to ensure that 
the temperature cycles were uniform. 
 
 
2.3.3 Slide evaluation 
All slides were further evaluated by 3 observers that used the same criteria, previously 
validated by a pathologist. Sections were evaluated in its totality and positivity was considered when 
10% or more of tumor cells stained specifically with a moderate to strong intensity. After an initial 
independent observation, all results were reviewed in group and a final result assigned to each case 
by consensus. Slide evaluation was blind to tumor characteristics and other clinical data.  
Step 
Time 
SIX1 SOX2 
1. Deparaffinization in Xylene 2 x 10min 
2. Rehydrate through decreasing concentrations of Ethanol - 
3. Wash in bidistilled water - 
4. Microwave the slides in 600mL of Tris-EDTA Buffer (pH 9.0) at 80% 
potency 20min 
5. Let the solution cool at room temperature 5min 
6. Wash the slides in running water 15min 
7. Block endogenous peroxidase activity with Hydrogen Peroxide at 3% 10min 
8. Wash in running water - 
9. Apply hydrophobic pen - 
10. Wash with PBS with Tween 20 at 0.05% - 
11. Incubate with blocking solution 20min (kit) 
12. Incubate with Primary Antibody (dilution) 60min (1/100) 30min (1/500) 
13. Wash in PBS with Tween 20 at 0.05% 2 x 5min 
14. Incubate with Secondary Antibody 30min (kit) 
15. Wash in PBS with Tween 20 at 0.05% 2 x 5min 
16. Incubate with DAB 5min 
17. Wash in running water 2min 
18. Counterstain in Mayer’s Hematoxylin 2min 
19. Wash in running water 5min 
20. Dehydrate through increasing concentrations of Ethanol and Xylene - 
21. Mount with Entellan® - 
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Afterward, images were captured at the Pathology Department of Egas Moniz Hospital with a 
Leica DFC320 digital camera coupled to a Leica DM1000 microscope using Leica IM50 software. 
2.4 Data Treatment 
Statistical analyzes were carried out with IBM® SPSS® Statistics 20 in order to properly 
interpreted all collected data. Fisher’s exact test was employed for categorical data analysis and 
Fisher-Freeman-Halton test when contingency tables were larger than 2x2; t-test was applied to 
interval variables and the Mann-Whitney test for non-normal distributions. Statistical significance was 
established at P < 0.05. 
 
 
31 
 
3 Results 
3.1 Sample characterization 
45 samples were analyzed corresponding to 43 patients. Women’s mean age at diagnosis 
was 62 years (range 42-84), mean age of menarche 13 years (range 9-15) and the mean age of 
menopause 49 years (range 36-59). On average women had 2 pregnancies (range 0-8) and a 
mean body mass index (BMI) of 26.56 (range 19.23-38.58). 37.8% of them have used oral 
contraceptives and 15.0% had hormone replacement treatment. Relatively to the tumors, 71.1% 
were invasive carcinomas NOS (Fig. 3.1), 8.9% were invasive lobular carcinomas (Fig. 3.2), and 
the remaining were carcinomas in situ (6.7%), mucinous carcinomas (6.7%), invasive papillary 
carcinomas (2.2%), invasive micropapillary carcinoma (2.2%) and a medullary carcinoma (2.2%). 
86.4% of the samples were estrogen positive, 79.1% progesterone positive, 13.6% HER2 positive 
and 45.5% high ki67. Accordingly, 42.2% of the tumors were Luminal A, 31.1% Luminal B (HER2-), 
11.1% Luminal B (HER2+), 6.7% Basal-Like, and 6.7% match in situ carcinomas and therefore 
weren’t categorized. The most abundant grade was II representing 65% of all tumors, and the 
stage was IA, representing 30.2% of all tumors. miRNA quantification reveal that miR-200c was 
downregulated in 12.8% of the samples and upregulated in 23.1%. As for miR-203, 20.5% samples 
presented downregulation and 30.8% upregulation. Tumor classification and clinical information are 
summarized in Table 3.1 and Table 3.2. 
Additional characteristics like ethnicity and alcohol consumption, among others, were not 
evaluated due to the substantial lack of data for all patients. 
 
 
 
 
Fig. 3.1 Invasive carcinoma, NOS. 
Malignant cells form nests with small ductal 
structures. The stroma is very fibrotic. Hematoxylin 
and Eosin stain (20x). 
Fig. 3.2 Invasive lobular carcinoma. 
Malignant cells infiltrate the stroma next to a 
normal duct. Hematoxylin and Eosin stain (40x). 
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Table 3.1 Frequency analysis of clinical 
parameters. 
Table 3.2 Frequency analysis of pathological 
parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a BMI: Body Mass Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Downregulated: fold change ≤ -2.5 
b Upregulated: foldchange ≥ 2.5. 
Characteristics Value 
Histopathological Type (%) 
Carcinoma In Situ 3 (6.7%) 
Invasive carcinoma, NOS 32 (71.1%) 
Invasive lobular carcinoma 4 (8.9%) 
Mucinous carcinoma 3 (6.7%) 
Medullary carcinoma 1 (2.2%) 
Invasive papillary carcinoma 1 (2.2%) 
Invasive micropapillary carcinoma 1 (2.2%) 
Total 45 
Grade (%) 
I 7 (17.5%) 
II 26 (65.0%) 
III 7 (17.5%) 
Total 40 
Estrogen receptor (%) 
Negative 6 (13.6%) 
Positive 38 (86.4%) 
Total 44 
Progesterone receptor (%) 
Negative 9 (20.9%) 
Positive 34 (79.1%) 
Total 43 
HER2  (%) 
Negative 38 (86.4%) 
Positive 6 (13.6%) 
Total 44 
Ki67  (%) 
Negative 24 (54.5%) 
Positive 20 (45.5%) 
Total 44 
Molecular Subtype (%) 
Luminal A 19 (43.2%) 
Luminal B (HER2-) 14 (31.8%) 
Luminal B (HER2+) 5 (11.4%) 
Basal-Like 3 (6.8%) 
In Situ 3 (6.8%) 
Total 44 
Stage (%) 
0 1 (2.3%) 
IA 13 (30.2%) 
IB 8 (18.6%) 
IIA 10 (23.3%) 
IIB 9 (20.9%) 
IIIA 1 (2.3%) 
IIIC 1 (2.3%) 
Total 43 
miR-200c (%) 
Without variation 25 (64.1%) 
Downregulated a 5 (12.8%) 
Upregulated b 9 (23.1%) 
Total 39 
miR-203 (%) 
Without variation 19 (48.7%) 
Downregulated a 8 (20.5%) 
Upregulated b 12 (30.8%) 
Total 39 
Characteristics Value 
Age at Diagnosis 
Mean 62 
Range 42-84 
N 44 
BMI 
a
 
Mean 26,56 
Range 19.23-38.58 
N 40 
Age of Menarche 
Mean 13 
Range 9-15 
N 41 
Age of Menopause 
Mean 49 
Range 36-59 
N 32 
Number of Pregnancies 
Mean 2 
Range 0-8 
N 41 
Oral Contraceptives (%) 
No 22 (56.4%) 
Yes 17 (37.8%) 
Total 39 
Hormone Replacement Treatment (%) 
No 34 (85.0%) 
Yes 6 (15.0%) 
Total 40 
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3.2 Immunohistochemistry Optimization 
The optimal staining was considered the one which allowed specific intense staining in all 
expected structures of the sample used as control, with no background or nonspecific staining. 
Following this simple criterion, each variation to the protocol was evaluated during optimization of all 
the antibodies. 
Table 3.3 summarizes the outcome of all the variations tested per antibody. Only Anti-SIX1, 
clone CL0185 (Fig. 3.3), and Anti-SOX2, clone 10F10 (Fig. 3.4), immunostain were validated, all the 
other antibodies didn’t perform properly; for this reason ATM (Fig. 3.5) and BMI1 (Fig. 3.6) could not be 
assessed in the tumor samples. 
Table 3.3 Outcome of immunohistochemistry technique optimization. 
Antibody Specifications Slides Outcome 
ATM 
rabbit, monoclonal, clone Y170, Millipore, lot 
2445819, ref. 04-200 5 Wrong structures stained 
rabbit, monoclonal, clone Y170, Millipore, lot 
2472976, ref. 04-200 3 Wrong structures stained 
BMI1 
mouse, monoclonal, clone 229F6, Nordic-MUbio, 
lot 1362, ref. MUB2004S 17 Lack of staining 
mouse, monoclonal, clone 10H8, Cell Applications, 
lot 101, ref. CB16351 12 Overstaining 
SIX1 
rabbit, polyclonal, Sigma-Aldrich, lot B40182, ref. 
HPA001893 34 Unspecific staining 
mouse, monoclonal, clone CL0185, Sigma-Aldrich, 
lot 02582, ref. AMAb90544 18 Optimal staining 
SOX2 
rabbit, polyclonal, Sigma-Aldrich, lot 061M0604, 
ref. S9072 23 Overstaining 
mouse, monoclonal, clone 10F10, Sigma-Aldrich, 
lot PM12110682, ref. SAB5300177 15 Optimal staining 
 
 
 
 
Fig. 3.3 Normal cervix stained for SIX1. 
Only the nuclei of glandular epithelium express the protein, as 
expected (20x). 
Fig. 3.4 Normal tonsil stained for SOX2. 
Only the nuclei of stratified epithelium express the protein, as 
expected (20x). 
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3.3 Immunohistochemistry Results 
The tumor sections stained for SIX1 and SOX2 were evaluated in its totality by all 3 observers. 
After an initial independent observation, all results were reviewed in group and a final result assigned 
to each case by consensus. Positivity was considered when 10% or more of tumor cells stained with a 
moderate to strong intensity (Fig. 3.7). In sum, 13.3% of tumors were SIX1-positive (Fig. 3.8, Fig. 3.9 
and Fig. 3.10) and 8.9% were SOX2-positive (Fig. 3.11, Fig. 3.12 and Fig. 3.13). Only 2 tumors were 
positive for both. All positive cases exhibited normal mammary gland cells negatively stained. In each 
run, the control tissue performed accordingly. Most of the tumor sections had poorly preserved 
morphology that occurred during the antigen retrieval step that was too harsh to the tissues due to 
their insufficient paraffin impregnation (Fig. 3.14). However, morphology did not jeopardize evaluation 
since there were tumor cells present in all cases. 
Fig. 3.7 Results of slide evaluation of SIX1 and SOX2 immunostain. 
Fig. 3.5 Normal breast stained for ATM. 
Nuclei, that should be expressing the protein, appear blue. Only 
neutrophils appear to be stained, cytoplasmically (20x). 
Fig. 3.6 Normal breast stained for BMI1. 
Every structure appears to be stained, even at an antibody 
dilution of 1/1500, clearly indicating its unspecificity (20x). 
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Fig. 3.8 SIX1 positive invasive lobular carcinoma. 
Same case as Fig. 3.2 (40x). 
Fig. 3.9 SIX1 positive invasive carcinoma NOS. 
(20x). 
Fig. 3.10 SIX1 negative invasive carcinoma NOS. 
(20x). 
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Fig. 3.11 SOX2 positive invasive carcinoma NOS. 
Same case as Fig. 3.1 (20x). 
Fig. 3.12 SOX2 negative invasive carcinoma NOS. 
(20x). 
Fig. 3.13 Mast cells stained with anti-SOX2 antibody.  
Same case as Fig. 3.12 where it can be seen mast cells exhibiting 
completely normal unspecific cytoplasmic granular staining (40x). 
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3.4 Statistical analysis 
The results of statistical analysis are summarized in Table 3.4, Table 3.5, Table 3.6, Table 3.7, and 
Table 3.8. None of the characteristics analyzed exhibited relation with the immunohistochemical 
expression of both SIX1 and SOX2 except for the number of pregnancies. SIX1 expression appears to 
be statistically associated with the number of pregnancies (p-value=0.034), being its positivity related 
with multiple pregnancies. SOX2 does not show the same pattern. Although not statistically relevant, 
SOX2 displays a certain trend relatively to age at diagnosis (p-value=0.108), BMI (p-value=0.123) and 
ER (p-value=1.000) since all the positive cases are above 62 years of age at diagnosis, above a BMI 
of 25 (overweight) and all ER positive. Furthermore, SIX1 expression was not associated with SOX2 
expression (p-value=0.08). 
The association between miR-200c and miR-203 levels with clinicopathological features was 
not a purpose of this study, however, their statistical analysis was performed and did not reveal any 
statistically significant association. Accordingly, it was decided not to include this data. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.14 Poor tissue preservation. 
Example of poor tissue preservation found in an invasive lobular carcinoma and in an invasive carcinoma, NOS. Note the 
tattered aspect of these sections and the presence of folded regions (4x). 
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Table 3.4 Association between clinical parameters and immunohistochemical expression of SIX1 and 
SOX2. 
 
SIX1 SOX2 
- + Total P-value
a
 - + Total P-value
a
 
Age at Diagnosis 
< 62 20 2 22 
0.664 
22 0 22 
0.108 ≥ 62 18 4 22 18 4 22 
Total 38 6 44 40 4 44 
BMI 
< 24.99 (normal weight) 15 2 17 
1.000 
17 0 17 
0.123 ≥ 25 (overweight) 20 3 23 19 4 23 
Total 35 5 40 36 4 40 
Age of Menarche 
< 13 16 3 19 
0.649 
17 2 19 
1.000 ≥ 13 20 2 22 20 2 22 
Total 36 5 41 37 4 41 
Age of Menopause 
< 49 10 1 11 
1.000 
8 3 11 
0.106 ≥ 49 18 3 21 20 1 21 
Total 28 4 32 28 4 32 
Oral 
Contraceptives 
Yes 16 1 17 
0.363 
16 1 17 
1.000 No 18 4 22 20 2 22 
Total 34 5 39 36 3 39 
Hormone 
Replacement 
Treatment 
Yes 5 1 6 
1.000 
5 1 6 
0.493 No 30 4 34 31 3 34 
Total 35 5 40 36 4 40 
 
(+) Positive; (-) Negative; BMI: Body Mass Index.  
a Fisher’s Exact Test. 
 
 
Table 3.5 Association between number of pregnancies and immunohistochemical expression of SIX1 and 
SOX2. 
 
SIX1 SOX2 
- + P-value
a
 - + P-value
a
 
Number of pregnancies
b
 
N 36 5 
0.034 
37 4 
0.212 
Mean 1.83 3.80 1.95 3.25 
Std. Deviation 1.81 2.39 1.78 3.40 
Std. Error Mean 0.30 1.07 0.29 1.70 
 
(+) Positive; (-) Negative.  
a t-test. 
b Kolmogorov-Smirnov test indicates that this variable has Normal distribution (p-value=0.170) and 
Levene's Test demonstrates that equal variances are assumed (p-value=0.600 for SIX1 and p-
value=0.120 for SOX2). 
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Table 3.6 Association between tumor characteristics and immunohistochemical expression of SIX1 and 
SOX2. 
 
(+) Positive; (-) Negative.  
a Fisher’s Exact Test and Fisher-Freeman-Halton Test 
 
 
  SIX1 SOX2 
  - + Total P-valuea - + Total P-valuea 
Histopathological 
Type 
Carcinoma In Situ 3 0 3 
0.889 
3 0 3 
0.156 
Invasive carcinoma, 
NOS 
27 5 32 30 2 32 
Invasive lobular 
carcinoma 
3 1 4 4 0 4 
Medullary carcinoma 1 0 1 1 0 1 
Mucinous carcinoma 3 0 3 2 1 3 
Invasive papillary 
carcinoma 
1 0 1 0 1 1 
Invasive micropapillary 
carcinoma 
1 0 1 1 0 1 
Total 39 6 45 41 4 45 
Grade 
I 6 1 7 
1.000 
6 1 7 
0.602 
II 22 4 26 24 2 26 
III 6 1 7 6 1 7 
Total 34 6 40 36 4 40 
Estrogen Receptor 
Negative 6 0 6 
0.573 
6 0 6 
1.000 Positive 32 6 38 34 4 38 
Total 38 6 44 40 4 44 
Progesterone 
Receptor 
Negative 6 3 9 
0.095 
8 1 9 
1.000 Positive 31 3 34 31 3 34 
Total 37 6 43 39 4 43 
HER2 
Negative 32 6 38 
0.573 
34 4 38 
1.000 Positive 6 0 6 6 0 6 
Total 38 6 44 40 4 44 
Ki67 
Negative 20 4 24 
0.673 
22 2 24 
1.000 Positive 18 2 20 18 2 20 
Total 38 6 44 40 4 44 
Molecular Subtype 
Luminal A 16 3 19 
0.938 
18 1 19 
0.528 
Luminal B (HER2-) 11 3 14 11 3 14 
Luminal B (HER2+) 5 0 5 5 0 5 
Basal-Like 3 0 3 3 0 3 
In Situ 3 0 3 3 0 3 
Total 38 6 44 40 4 44 
Stage 
0 1 0 1 
1.000 
1 0 1 
0.421 
IA 11 2 13 13 0 13 
IB 7 1 8 6 2 8 
IIA 8 2 10 9 1 10 
IIB 8 1 9 8 1 9 
IIIA 1 0 1 1 0 1 
IIIC 1 0 1 1 0 1 
Total 37 6 43 38 4 43 
miR-200c Regulation 
Without Variation 21 4 25 
1.000 
22 3 25 
1.000 
Down Regulation 5 0 5 5 0 5 
Up Regulation 8 1 9 8 1 9 
Total 34 5 39 35 4 39 
miR-203 Regulation 
Without Variation 14 5 19 
0.082 
16 3 19 
0.800 
Down Regulation 8 0 8 8 0 8 
Up Regulation 12 0 12 11 1 12 
Total 34 5 39 35 4 39 
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Table 3.7 Association between miRNAs fold-change and immunohistochemical expression of SIX1 
and SOX2. 
 
 
SIX1 SOX2 
- + P-value
a
 - + P-value
a
 
miR-200c Fold
b
 N 34 5 0.356 35 4 0.876 
miR-203 Fold
b
 N 34 5 0.610 35 4 0.911 
 
(+) Positive; (-) Negative.  
a  Mann-Whitney’s test. 
b Kolmogorov-Smirnov test indicates that these variables don’t follow a 
Normal distribution (p-value=0.000 for both SIX1 and SOX2). 
 
 
 
Table 3.8 Association between immunohistochemical expression of SIX1 with SOX2. 
 
 
SIX1 
P-value
a
 
0.080 
- + Total 
SOX2 
- 37 4 41 
+ 2 2 4 
Total 39 6 45 
 
(+) Positive; (-) Negative.  
a  Fisher’s Exact Test. 
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4 Discussion 
miR-200 family consists of five members that includes miR-200c. They cooperatively down-
regulate the E-cadherin transcriptional repressors zinc finger E-box binding homeobox 1 (ZEB1, also 
known as dEF1) and Smad interacting protein 1 (SIP1, also known as ZEB2) implicated in EMT and 
tumor metastasis (Serpico, 2013; Singh & Mo, 2013). As regards to miR-203, this miRNA is a key 
molecule involved in the induction of apoptosis or cell cycle arrest, and inhibition of EMT, migration 
and invasion. Taken together with the fact that miR-203 is upregulated in nonmetastatic breast cancer 
cell lines (MCF-7) when compared to non-tumorigenic cells (MCF-10A) but absent in metastatic cell 
lines (MDA-MB-231), it could be speculated that miR-203 is upregulated in primary breast cancers to 
restrain metastatic behavior, and downregulation of miR-203 may be a mechanism by which cancer 
cells can acquire an aggressive, pro-metastatic phenotype (DeCastro et al., 2013; Liu, 2012; Zhang et 
al., 2011). Therefore, the study of such miRNAs may impact the understanding of the functioning of 
the tumor cells and this information can be used to predict tumor behavior and, ultimately halting its 
proliferation. The therapeutic use of miRNAs is far from being a reality however, it can perhaps be 
used as tumor markers to better characterize them. Since the effect of miRNA is closely associated 
with the numerous regulated targets, its true potential as a marker depend on the expression of these 
same targets. Hence the relevance of this work to try to understand if the levels of miR-200c and miR-
203 can have an impact as cancer markers through the expression of putative targets involved in 
tumorigenesis and tumor progression. 
The 45 studied samples were randomly selected from the biobank therefore; a major concern 
was if these samples represented properly the diversity of cases in the biobank. In the selected 
samples, 71,1% were invasive carcinoma NOS and 8.9% invasive lobular carcinomas, which portrays 
the 66.4% of invasive carcinoma NOS and 12.6% of invasive lobular carcinomas of the biobank. 
Additionally, these values reflect published data as invasive carcinoma NOS represents approximately 
40% to 70% of tumors, and invasive lobular carcinomas 5% to 15% (Sandhu et al., 2010; WHO, 
2012). Regarding molecular patterns, the 45 samples reveal ER positivity in 86.4% of the cases, PR 
positivity in 79.1%, HER2 positivity in 13.6% and high ki67 in 45.5%. This values follow the ones found 
in the totality of the biobank: 88.8% of ER positive samples, 82.3% PR positive, 12.3% HER2 positive 
and 46.5% high ki67. These results could permit a generalization of the data obtained with the 45 
samples to the rest of the biobank. 
Regarding immunohistochemistry data, ATM nuclear staining of normal breast epithelium, 
myoepithelial cells, and fibroblasts can serve as an internal positive control (Fig. 4.1). For that reason 
the absence of nuclear staining in normal breast tissue, using the antibodies purchased, could not be 
validated. Conversely, BMI1 expression was excluded from this study since it’s expected to stain just 
the nuclei of normal breast (Fig. 4.2) and not the whole tissue. Anti-SIX1 and Anti-SOX2 antibodies 
performed well and as expected, which allowed validating the immunostaining and, subsequently, 
apply them to the tumor samples. In the breast cancer samples the technique did not perform as 
anticipated, since there was extensive loss of architectural detail within loose connective and adipose 
tissue that may reflect inadequate fixation or faults in tissue processing, such as too short a 
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processing cycle and/or use of exhausted reagents. Because these samples were handed to us after 
being previously diagnosed and quantified for miRNAs, we could only try to potentiate tissue adhesion 
but not revert their poorly processed state. Nonetheless, due to adhesion slides and thinner sections 
there were always tumor cells to evaluate for the expression of SIX1 and SOX2. 
 
SIX1 is involved in the development of many tissues and organs, and their levels vary, throughout 
developmental stages from embryo to adulthood, suggesting that there may be a basic promoter 
sequence to maintain its basic expression in these various contexts (Jin et al., 2014; Wu et al., 2014). 
On the other hand, SOX2 is widely regarded as a key founding member of the cohort of core 
transcription regulators that controls pluripotency and self-renewal in embryonic stem cells by 
physically interacting with OCT4 and NANOG forming a protein complex that binds the promoters of 
numerous stem cell differentiation factors, suppressing their expression. Thus, SOX2 plays critical 
roles in the embryonic development of several tissues and in organogenesis, and therefore it is likely 
to be involved in self-renewal and precursor differentiation (Huang et al., 2014; Lengerke et al., 2001; 
Tam & Ng, 2014; Zhang et al., 2012). Due to their role as general transcription factors promoting cell 
proliferation, SIX1 and SOX2 have been implicated as potential cancer markers. However, to date, 
little is known about their role in breast cancer tumorigenesis. 
In this study, 13.3% of the samples were SIX1 positive. These results do not follow the trend 
found in a study conducted in China in 2014 by Jin and colleagues on 314 patients, where IHC 
analysis revealed a significantly higher strongly positive rate of SIX1 protein in breast cancer (61.8%) 
and carcinoma in situ (23.1%) compared with adjacent normal breast tissues (6.7%). They also 
concluded that SIX1 protein expression was significantly correlated with clinical stage, lymph node 
metastasis and Her2 expression status, suggesting that SIX1 may be a useful marker for prognostic 
evaluation of breast cancer.  On the contrary, our results showed no association with any of the 
clinicopathological characteristics analyzed, except for the number of pregnancies where positivity is 
associated with multiple pregnancies. This may be counter intuitive since women who have had no 
children or who had their first pregnancy after age 30 are the ones who have a slightly higher breast 
Fig. 4.1 ATM expression by immunohistochemistry 
in normal breast tissue.  
Source: 
http://www.proteinatlas.org/ENSG00000149311/tissue/
breast 
Fig. 4.2 BMI1 expression by immunohistochemistry 
in normal breast tissue.  
Source: 
http://www.proteinatlas.org/ENSG00000168283/tissue/b
reast 
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cancer risk (Vogel, 2000; ; WHO, 2012; Yager & Davidson, 2006). Additionally, there seems to be a 
variation about the accurate location of SIX1 using different antibodies since the protein has been 
seen in both cytoplasm and nucleus. Hence, further studies are required to elucidate the mechanism 
that regulates SIX1 homeoprotein localization in order to properly understand its expression and 
influence in a cellular context. Moreover, according to TargetScan, SIX1 mRNA is targeted by several 
miRNAs including miR-200c but, in our study it was not possibly to conclude that miR-200c levels 
could be related to SIX1 protein levels. Even more, none of the positive cases had miR-200c 
downregulated, as it should be expected. 
Relatively to SOX2 expression, 8.9% of analyzed samples were positive. These results do not 
fit with those of other studies such as the one of Lengerke and colleagues performed in Germany in 
2011 with 95 patients, wherein 27.9% of analyzed samples of invasive breast carcinoma were SOX2 
positive such as 44.4% of carcinomas in situ. In another study of Huang and colleagues, carried out in 
2014 in China with 609 samples, SOX2 was detected in 19.0% of invasive breast carcinomas and 
12.3% carcinomas in situ. This study also showed that SOX2 expression was associated closely with 
high histological grade, large tumor size, molecular subtypes with adverse outcome (preferably 
expressed in basal-like breast cancers), negative hormone receptors status and high proliferation 
index, in other words, SOX2 contributes to a less differentiated state, tumor progression and lymph 
node metastasis in breast cancer. However, in our study SOX2 expression could not be associated 
with any of those characteristics, neither with the other characteristics assessed. There seems to be a 
trend, although not statistically relevant, of SOX2 with higher body mass index and higher age at 
diagnosis which could indicate a possibly expression of SOX2 in women with more percentage of 
body fat, which is known to be associated with higher estrogen levels. Curiously, all the SOX2 positive 
cases are also ER positive, even though this association is not statically relevant. Nonetheless, the 
number of positive cases probably did not allow us to draw a conclusion. Furthermore, although SOX2 
mRNA is, according to Targetscan, a target of miR-200c and that it is described in vivo in colorectal 
carcinoma that they are involved in a feedback loop regulation (Lu et al. 2014), we did not find any 
association between the two of them in our study and again, no positive cases were found with miR-
200c downregulation. 
There are few studies regarding the expression of SIX1 and SOX2 in human patients with 
breast cancer and as far as we know, there are no studies that characterize the Portuguese population 
for expression of both proteins. As such, a conclusion we can draw from our study is that, in fact, in 
the Portuguese population breast cancers we observe relatively low levels of SIX1 and SOX2, 13.3% 
and 8.9%, respectively. Furthermore, we could not find a statistically significant association between 
the expression of both proteins and various clinicopathological parameters, except for the number of 
pregnancies that seems to be associated with SIX1positivity (p-value = 0.034). Regarding the 
relationship between levels of miR-200c and expression of their putative targets, SIX1 and SOX2, it 
was also not possible to find a statistically significant association. This may be due to the rather small 
sample size used in this study, which restricts us from drawing well established conclusions.  
Therefore, we should continue to analyze the rest of samples that already exist in the biobank 
(76 samples) in order to increase the sample size and thus increase the robustness of the results. 
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Additionally, because SIX1 and SOX2 are actually transcription factors generally acting in 
transcriptional complexes, the mere expression of one these proteins can have no relevance in 
understanding the behavior of the tumor cell but rather a set of markers should be evaluated in order 
to correctly predict their behavior. As such several interacting proteins could have a greater impact on 
the understanding of the final results of dysregulated pathways instead of just one. This would be a 
wiser approach in the future. Also, as a complement, it would be interesting to assess in the same 
samples the levels of SIX1 and SOX2 mRNA to determine whether they may indeed be a link between 
miRNAs and these proteins expression and in cases where protein was not detected if expression of 
their respective gene indeed occurs. A clinical aspect which was not possible to evaluate with this 
study was the therapeutic outcome. In this sense, it would be enriching to follow-up these patients 
assessing after five years the relationship between SIX1 and SOX2 with the effectiveness of therapy, 
recurrence, and survival. Regarding the technical procedure, as ATM and BMI1 are important cancer 
markers candidates one should test other antibodies that would function as expected. Moreover, in 
order to minimize the poor tissue morphology observed, immunohistochemistry should be executed on 
automated staining instruments which are less aggressive to the tissue sections than the technique 
performed manually and allow more reproducible results. 
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